B. Riley Securities Maintains Buy on PDS Biotechnology, Lowers Price Target to $9
Portfolio Pulse from Benzinga Newsdesk
B. Riley Securities has maintained its Buy rating on PDS Biotechnology (NASDAQ:PDSB) but lowered the price target from $11 to $9.

June 12, 2024 | 2:15 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
B. Riley Securities has maintained its Buy rating on PDS Biotechnology but lowered the price target from $11 to $9.
The Buy rating suggests continued confidence in the company's prospects, but the lowered price target indicates some caution. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100